Latest Headlines

Latest Headlines

FDA castigates Indian drugmaker over mess at API plant

If the holes in the ceiling and walls allowing pigeons to fly around manufacturing equipment at India's Pan Drugs were not enough to warrant an FDA warning letter, then the fact that it also was not thoroughly testing its APIs did the trick.

Germany's leon-nanodrugs GmbH bags $20M for its reformulation platform

Germany's leon-nanodrugs GmbH announced the closure of its €18.5 ($20.4 million) Series A preferred stock offering. The company develops oral and parenteral reformulations of generic active pharmaceutical ingredients using its patented MJR nanotechnology platform.

Pozen has a new CEO to deal with the FDA's API concerns

When drugmaker Pozen got a second FDA complete response letter tied to issues with its API supplier, the company insisted it had already done everything the agency asked.

Recipharm bets on a U.S. biotech with an R&D joint venture

Swedish contract drug developer Recipharm has signed a deal with Virginia's Synthonics, investing in the biotech and lending its expertise in the development of new compounds.

Indonesia pharma exec sees progress on sales outlook, API supplies

Indonesia drugmakers expect to emerge from a long period of a depressed currency to almost double industry sales this year, according to one of the pharma leaders.

FDA bans two more IPCA plants

After issuing an import alert last year for an IPCA Laboratories API plant in India where employees had been falsifying drug testing results and deleting failed tests, the FDA began looking at its operations further upstream and has now banned products from two of IPCA's finished product facilities.

India threatens restrictions on China pharma imports

India's government has threatened to place restrictions on imports of nonessential items, including pharmaceuticals, from China if it does not ease some of its "protectionist tendencies" toward India products.

Norway's Weifa bets growth on separate API biz

Norwegian drugmaker Weifa figures its consumer health biz and its contract active pharmaceutical ingredient operations both have a better shot at growth if they go their separate ways. To make that happen, Weifa plans on spinning the API business off into a contract manufacturing operation, with its first contract to make the APIs for Weifa.

FDA spanks second Novacyl Asian API plant with warning letter

The FDA has cited a Novacyl active pharmaceutical ingredient (API) manufacturing plant in Thailand with a warning letter after finding some of the same issues there that it had uncovered at the company's facility in China.

India plans to ramp up API output to ease China imports

India drug authorities are working on plans to increase the nation's capacity to produce its own bulk drugs in an effort to reduce its drug industry's dependence on imports, mainly from China.